Home › Research › Tau biomarkers
Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias
Howard E, Irwin DJ, Rascovsky K, Nevler N, Shellikeri S, Tropea TF, Spindler M, Deik A et al.. Neurology, 2021-02-16
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective To determine whether patients with Lewy body dementia (LBD) with likely Alzheimer disease (AD)-type copathology are more impaired on confrontation naming than those without likely AD-type copathology. Methods We selected 57 patients with LBD (dementia with Lewy bodies [DLB], n = 38; Parkinson disease dementia [PDD], n = 19) with available AD CSF biomarkers and neuropsychological data. CSF β-amyloid 1-42 (Aβ 42 ), phosphorylated-tau (p-tau), and total-tau (t-tau) concentrations were measured.
What this study adds
Evidence grade: Low
The record lists 38 participants. In this group of 57 patients with Lewy body dementia, those who also had likely Alzheimer-type copathology were more impaired on a naming test than those without it. This suggests that Alzheimer-type changes can add to the cognitive problems of people with Lewy body dementia, but it does not test any treatment.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Howard, E., Irwin, D. J., Rascovsky, K., Nevler, N., Shellikeri, S., Tropea, T. F., et al. (2021). Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias. Neurology. https://doi.org/10.1212/wnl.0000000000011699
Vancouver
Howard E, Irwin DJ, Rascovsky K, Nevler N, Shellikeri S, Tropea TF, et al. Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias. Neurology. 2021. doi:10.1212/wnl.0000000000011699. PMID: 33593865.
BibTeX
@article{howard2021-33593865,
author = {Howard, E. and Irwin, D. J. and Rascovsky, K. and Nevler, N. and Shellikeri, S. and Tropea, T. F. and Spindler, M. and Deik, A. and others},
title = {{Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias}},
journal = {Neurology},
year = {2021},
doi = {10.1212/wnl.0000000000011699},
pmid = {33593865},
url = {https://doi.org/10.1212/wnl.0000000000011699}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Methods We selected 57 patients with LBD (dementia with Lewy bodies [DLB], n = 38; Parkinson disease dementia [PDD], n = 19) with available AD CSF biomarkers and neuropsychological data.
- CSF β-amyloid 1-42 (Aβ 42 ), phosphorylated-tau (p-tau), and total-tau (t-tau) concentrations were measured.
- We used an autopsy-validated CSF cut point (t-tau:Aβ 42 ratio > 0.3, n = 43), or autopsy data when available (n = 14), to categorize patients as having LBD with (LBD + AD, n = 26) and without (LBD - AD, n = 31) likely AD-type copathology.
- Analysis of covariance tested between-group comparisons across biologically defined groups (LBD + AD, LBD - AD) and clinical phenotypes (DLB, PDD) on confrontation naming (30-item Boston Naming Test [BNT]), executive abilities (letter fluency [LF], reverse digit span [RDS]), and global cognition (Mini-Mental State Examination [MMSE]), with adjustment for age at dementia onset, time from dementia onset to test date, and time from CSF to test date.
Why it matters
In this group of 57 patients with Lewy body dementia, those who also had likely Alzheimer-type copathology were more impaired on a naming test than those without it. This suggests that Alzheimer-type changes can add to the cognitive problems of people with Lewy body dementia, but it does not test any treatment.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants38
- Evidence strengthLow
How this study scored 48/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 38 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 49 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 7.0 citations a year over 7 year(s) since 2021 |
| Impact for its field and year | 3 / 6 | Cited 6.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 7 other studies in this library |
| Still being cited | 2 / 4 | Cited 21 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Katheryn A Q Cousins: h-index 25 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Philadelphia VA Medical Center: institution h-index 357 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33593865) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1212/wnl.0000000000011699
- PubMed: 33593865
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 27.
Later studies that cite this one
7 studies in the alzhub library list this one in their references.
Related studies in Tau biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.